Michael Gates, MD
Family Medicine · Pittsburgh, PANPI 1265408348
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 431 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 32.7% of the total. Reporting peaked in 2023 at $1,664 and has fallen 55.1% since, to $747 in 2025. Among family medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 431 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$1K
- Novo Nordisk$1K
- GSK$679
- Amgen$259
- Bayer$257
- plus $1K from 20 others
Across 75 payments — averaging $8011.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$424K
- Novartis$143K
- AbbVie$33K
What the payments were for
- Travel & lodging$6048%
- Food & beverage$6,66192%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 170 | $2,374 |
| Pfizer | 43 | $1,370 |
| Novo Nordisk | 94 | $1,235 |
| GSK | 43 | $679 |
| Amgen | 15 | $259 |
| Bayer | 10 | $257 |
| Lilly USA, LLC | 14 | $242 |
| Teva Pharmaceuticals USA, Inc. | 6 | $141 |
| Lundbeck LLC | 5 | $119 |
| Abbott | 5 | $104 |
| UCB, Inc. | 3 | $81 |
| Phathom Pharmaceuticals, Inc. | 3 | $62 |
| Upsher-smith Laboratories LLC | 2 | $50 |
| AstraZeneca | 3 | $45 |
| Boehringer Ingelheim | 3 | $41 |
| Edwards Lifesciences | 1 | $33 |
| Novartis | 2 | $29 |
| Almatica Pharma LLC | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Otter Pharmaceuticals, LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
How this compares
$7,269 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 191 | $188,560 |
| EliquisApixaban | 136 | $122,567 |
| MounjaroTirzepatide | 83 | $95,778 |
| OzempicSemaglutide | 61 | $89,996 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $71,742 |
| RybelsusSemaglutide | 29 | $50,051 |
| XareltoRivaroxaban | 40 | $22,468 |
| UbrelvyUbrogepant | 13 | $19,833 |
| FarxigaDapagliflozin Propanediol | 14 | $10,585 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,526 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $6,673 |
| LinzessLinaclotide | 11 | $6,623 |
| Atorvastatin Calcium | 557 | $5,609 |
| Mesalamine | 12 | $3,442 |
| Buprenorphine | 24 | $3,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $41 | $188,560191 claims |
| Novo NordiskOzempic, Rybelsus | $1,235 | $140,04890 claims |
| PfizerEliquis | $1,370 | $122,567136 claims |
| Lilly USA, LLCMounjaro | $242 | $95,77883 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $679 | $79,26792 claims |
| AbbVieUbrelvy, Linzess, Synthroid | $2,374 | $28,32560 claims |
| AstraZenecaFarxiga | $45 | $10,58514 claims |
| Almatica Pharma LLCSertraline Hcl | $21 | $1,34470 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Pittsburgh
- Nathan BennettPittsburgh$465K
- Deborah GilboaPittsburgh$60K
- Gregory JaffePittsburgh$38K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.